Xiaoling Zhang, PhD.

Xiaoling Zhang, PhD. has worked in the field of Translational Medicine since 1997. Xiaoling began their career at Amgen Inc. as a Postdoctoral Research Fellow, where they progressed to Principal Scientist, Oncology Research. In 2012, they joined Dako North America-Agilent Technologies as the Scientific and Clinical Lead, Companion Diagnostics, where they developed PD-L1 companion diagnostic and worked on clinical biomarker study design and protocol development. In 2016, Xiaoling joined MedImmune-A member of the AstraZeneca Group as a Diagnostic Expert-Oncology Translational Medicine. Most recently, Xiaoling has been working as the Executive Director/Head of Translational Medicine at Apollomics since 2018.

Xiaoling Zhang, PhD. has an education history that includes a Doctorate in Molecular Cell Biology and Biochemistry from Washington University School of Medicine in St. Louis (1997), a Master of Science in Biology, Ecology, and Biostatistics from Southern Illinois University, Carbondale (1992), and a Bachelor of Science in Biology from Nankai University, Tianjin, China.